Gain Therapeutics, Inc cash flow statement GANX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Gain Therapeutics, Inc used $18.5 million of cash from operations, up 2.2% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021
Operating
Depreciation and amortization	0 +15.8%	0 +11.9%	0 +0.6%	0 +30.3%	0 +314.4%	0
Stock-based compensation	2 +10.4%	2 -24.6%	2 -26.7%	3 +113.5%	2 +81.9%	1
Operating cash flow	-19 -2.7%	-18 +2.2%	-19 -0.0%	-19 -28.4%	-15 -18.8%	-12
Investing
Capital expenditures	—	—	0 +46.5%	0 -87.1%	0 +26.3%	0
Investing cash flow	—	—	5 -51.3%	10 +169.2%	-15 -15582.5%	-0
Financing
Short-term debt repaid	0 +9.2%	0 +6.2%	0 +2.0%	0 +13.1%	0 +258.9%	0
Financing cash flow	25 +217.5%	28 +118.6%	13 +2.9%	13 +16147.6%	-0 -100.2%	42
Change in cash
Effect of exchange rate	-0 -104.6%	0 +189.9%	-1 -207.9%	0 +2152.4%	-0	—
Net change in cash	6 +162.4%	10 +840.8%	-1 -131.5%	4 +115.2%	-30 -200.6%	29
Free cash flow	—	—	-19 -0.1%	-19 -27.5%	-15 -18.9%	-12
Per share
Free cash flow per share	—	—	-0.83 +43.1%	-1.45 -16.4%	-1.25 -1.7%	-1.23
Ratios
Free cash flow margin	—	—	-34,244.87%	-34,217.53%	-11,166.38%	-9,303.42%
Capital expenditures to revenue	—	—	40.76%	27.83%	89.68%	70.35%
Stock-based compensation to revenue	—	—	4,331.57%	5,906.17%	1,150.81%	626.73%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: GANX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Bethesda, MD
SEC filer status: , Emerging growth company
SEC CIK: 1819411

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.